Company Profile

Xenex Disinfection Services LLC
Profile last edited on: 1/23/2019      CAGE: 6MLR5      UEI: DH6HDJRM1K27

Business Identifier: Destroying deadly microorganisms involved in hospital acquired infections (HAIs).
Year Founded
2008
First Award
2016
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

121 Interpark Boulevard Suite 104
San Antonio, TX 78216
   (210) 538-9300
   N/A
   www.xenex.com
Location: Single
Congr. District: 21
County: Bexar

Public Profile

Xenex's patented pulsed xenon Full Spectrum UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to eliminate harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide Founded by PhDs in epidemiology from Johns Hopkins, the Xenex mission is to save lives and reduce suffering by destroying deadly microorganisms that can cause hospital acquired infections (HAIs). Xenex devices are now included in infection control protocols in almost four hundred hospitals throughout the U.S. Pulsed Xenon Full Spectrum® UV disinfection is fast, safe, effective and proven. Traditional UV disinfection methodologies primarily achieve one type of cellular damage. LightStrike® Pulsed Xenon Full Spectrum® UV disinfection Robots leverage the full germicidal UV spectrum, achieving four primary methods of cellular damage. The Xenex LightStrike Germ-Zapping Robot® contains NO TOXIC MERCURY. Xenex is the only UV disinfection provider with multiple hospital customers reporting fewer infections in peer reviewed published studies.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
50-74

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $1,089,076
Project Title: Improving Patient Outcomes Through Tracking and Displaying the Disinfection Status of Equipment and Areas

Key People / Management

  Morris Miller -- CEO

  Joseph Authement -- Senior Vice President of Global Sales

  Paul Froutan -- Chief Operating Officer

  Irene Hahn -- Vice President of Client Services

  Melinda Hart

  Nita Schweitzer

  Julie Stachowiak -- Chief Epidemiologist

  Mark A Stibich -- Co-Founder & Chief Scientific Officer

  Shaun Walsh -- Vice President of Marketing

Company News

There are no news available.